1. Home
  2. SONO vs PHVS Comparison

SONO vs PHVS Comparison

Compare SONO & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sonos Inc.

SONO

Sonos Inc.

HOLD

Current Price

$14.03

Market Cap

1.8B

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$30.02

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SONO
PHVS
Founded
2002
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Consumer Electronics/Video Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.8B
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
SONO
PHVS
Price
$14.03
$30.02
Analyst Decision
Strong Buy
Buy
Analyst Count
3
11
Target Price
$19.67
$41.82
AVG Volume (30 Days)
1.1M
251.8K
Earning Date
05-04-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.52
N/A
Revenue
$1,443,276,000.00
N/A
Revenue This Year
$5.04
N/A
Revenue Next Year
$6.53
N/A
P/E Ratio
$19.78
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.65
$15.51
52 Week High
$19.82
$31.14

Technical Indicators

Market Signals
Indicator
SONO
PHVS
Relative Strength Index (RSI) 45.47 56.73
Support Level $12.60 $24.73
Resistance Level $14.15 N/A
Average True Range (ATR) 0.66 1.58
MACD 0.01 0.10
Stochastic Oscillator 43.35 74.83

Price Performance

Historical Comparison
SONO
PHVS

About SONO Sonos Inc.

Sonos Inc is an audio company dedicated to elevating life through sound, offering a connected platform that brings together music, movies, stories, and conversations. Its portfolio includes home theater speakers, components, plug-in and portable speakers and headphones, known for exceptional sound, thoughtful design, ease of use and seamless access to audio content. Its partner products and other revenue categories include accessories for home integration, such as custom-designed stands, mounts, and shelving units, along with partnerships for architectural speakers and automotive sound systems, as well as licensing, advertising revenue, and subscription-based services. The company operates in the United States and other countries, with the majority of revenue coming from the United States.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: